Novartis said it now expects core profit in the year to grow by a percentage in the mid to high teens range after it reported a 21% rise in core earnings in the third quarter, boosted by strong sale of key drugs.
Novartis said it now expects core profit in the year to grow by a percentage in the mid to high teens range after it reported a 21% rise in core earnings in the third quarter, boosted by strong sale of key drugs.